Amgen Inc. (AMGN)
| Market Cap | 146.27B |
| Revenue (ttm) | 32.53B |
| Net Income (ttm) | 4.23B |
| Shares Out | 537.53M |
| EPS (ttm) | 7.83 |
| PE Ratio | 34.74 |
| Forward PE | 13.17 |
| Dividend | $9.52 (3.50%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | 3,220,303 |
| Open | 276.00 |
| Previous Close | 269.43 |
| Day's Range | 269.78 - 276.97 |
| 52-Week Range | 253.30 - 346.85 |
| Beta | 0.56 |
| Analysts | Buy |
| Price Target | 324.05 (+19.09%) |
| Earnings Date | Feb 4, 2025 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; N... [Read more]
Financial Performance
In 2023, Amgen's revenue was $28.19 billion, an increase of 7.09% compared to the previous year's $26.32 billion. Earnings were $6.72 billion, an increase of 2.52%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for AMGN stock is "Buy." The 12-month stock price forecast is $324.05, which is an increase of 19.09% from the latest price.
News
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif. , Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today anno...
US FDA approves Amgen's colorectal cancer therapy
The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation.
Amgen Inc. (AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)
Amgen Inc. (NASDAQ:AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 January 13, 2025 6:00 PM ET Company Participants Robert Bradway - Chairman, CEO & President Conference Call Participants Ch...
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , Jan. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 J.P.
Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a clinica...
Amgen: The Buying Opportunity Has Now Arrived (Rating Upgrade)
Since my previous article, shares of Amgen meaningfully lagged the S&P 500 index. The company's revenue and non-GAAP EPS climbed higher in the third quarter. Amgen's deleveraging efforts are progressi...
Amgen's IMDYLLTRA®▼ (tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom
CAMBRIDGE, England--(BUSINESS WIRE)--Today, Amgen announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to IMDYLLTRA® for...
Amgen: Blockbusters, Emerging Therapies, And Investment Potential
Amgen's strong product portfolio and pipeline developments, including, but not limited to, IMDELLTRA and MariTide, support a "Strong Buy" rating for long-term investors despite upcoming patent expirat...
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
January Dow Dogs: 1 'Safer' Buy, And 5 With Promise
Verizon Communications is the only Dow Dog meeting the ideal of annual dividends from $1K invested, exceeding the single share price. Analysts forecast 11.36% to 31.73% net gains from the top ten Dow ...
Amgen stock price formed a death cross: will it rebound in 2025?
The Amgen stock price suffered a harsh reversal in the fourth quarter of 2024 as its weight loss drug failed to excite. After peaking at $341 in July, the stock plunged by over 25% to the current $260...
Will Dow Jones index 2024 losers become 2025 gainers?
The Dow Jones index has pulled back lately and fallen by over 5% from its December highs as bond yields soared. It ended the year at $42,665, down from last year's high of $45,000.
What's Going On With Amgen Stock On Friday?
On Friday, Novo Nordisk A/S NVO released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program.
PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises
LONDON--(BUSINESS WIRE)---- $AMGN #biotech--PESG Research Releases an Market Update Report on Silexion Therapeutics (NASDAQ: SLXN). The precision oncology sector has rapidly evolved into one of the mo...
Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value
Concentrate on a select few high-conviction stocks across different sectors to avoid "diworsification" and maximize returns, inspired by Charlie Munger and Warren Buffett. Utilize Joel Greenblatt's "M...
AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND
THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025.
BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding ...
Healthy Returns: Wall Street mulls over Amgen's weight loss drug data
Wall Street is chewing over data on Amgen's weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese drug company.
Amgen to invest $1 bln in North Carolina manufacturing site
U.S. drugmaker Amgen said on Thursday it will invest $1 billion towards a second drug substance manufacturing facility in North Carolina.
AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA
Investment Establishes Second Facility in Holly Springs; Builds on Previous $550M Commitment THOUSAND OAKS, Calif. , Dec. 5, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $1 billion expa...
Dow 30 December Dogs Show 28 Pay Dividends And 1 "Safer" Buy
Verizon is the only Dow Dog meeting the ideal of annual dividends from $1K invested exceeding its single share price. Five more Dow Dogs, including Cisco and Merck, are within 66% of meeting this idea...
Amgen Inc. (AMGN) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Amgen Inc. (NASDAQ:AMGN) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 10:00 AM ET Company Participants Peter Griffith - Executive Vice President and Chief Financial Officer J...